非小细胞肺癌抗血管生成药物治疗进展  

Progression of Anti-angiogenic Drug Therapy in Non-small Cell Lung Cancer

作　　者：张凯恋 褚倩[1] 陈元 ZHANG Kailian;CHU Qian;CHEN Yuan(Cancer Centre,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Oncology,Taikang Tongji Hospital,Wuhan 430050,China)

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤中心,武汉430030 [2]泰康同济(武汉)医院肿瘤科,武汉430050

出　　处：《医药导报》2018年第5期546-550,共5页Herald of Medicine

摘　　要：肿瘤新生血管形成是肿瘤生长、进展和转移的基础,涉及受体介导的各类细胞信号通路,以及许多促进/抑制血管生成的因子,其中刺激血管生成作用最强的生长因子是血管内皮生长因子(VEGF),其通过与血管内皮细胞生长因子受体(VEGFR)结合而发挥作用。VEGF/VEGFR通路抑制药目前已经广泛用于临床治疗,新一代抗肿瘤血管生成药物的研发亦取得一定突破。该文概述肿瘤血管生成机制及抗肿瘤血管生成不同分子通路,介绍了非小细胞肺癌抗肿瘤血管生成药物及耐药机制。Tumor neovascularization is the basis of tumor growth,progression and metastasis,involving various cell-mediated signal transduction pathways,and many factors that promote/inhibit angiogenesis.Among them,the strongest growth factor that stimulates angiogenesis is vascular endothelial growth factor(VEGF),which acts by binding to the vascular endothelial growth factor receptor(VEGFR).VEGF/VEGFR pathway inhibitors are now widely used in clinical treatment,a new generation of anti-tumor angiogenesis drug research and development has also made some breakthrough.This article reviews the mechanism of tumor angiogenesis,different molecules pathways of anti-tumor angiogenesis drugs and drug resistance mechanisms in the treatment of non-small cell lung cancer.

关 键 词：抗肿瘤血管生成药物 癌 肺 非小细胞 肿瘤新生血管形成 

分 类 号：R979.1[医药卫生—药品] R734.2[医药卫生—药学]